Activating transcription factor 6 alpha (referred to as ATF6 hereafter) is an endoplasmic reticulum (ER)-resident glycoprotein and one of the three sensors of the unfolded protein response (UPR). Upon ER stress, ATF6 is exported to the Golgi complex where it is cleaved by the S1P and S2P proteases thus releasing ATF6 cytosolic fragment and leading to the transcription of ATF6 target genes. In this study, we performed a phenotypic small-interfering RNA (siRNA) screening to better characterize the ER mechanisms involved in ATF6 activation upon ER stress. This revealed that silencing of ER-degradation-enhancing alpha-mannosidase-like protein-1 (EDEM1) increased the bioavailability of ER stress-induced ATF6 export to the Golgi complex through the stabilization of the natively unstable ATF6 protein. Moreover, we characterized a somatic variant of EDEM1 (N198I) found in hepatocellular carcinoma that alters ATF6 signaling and might provide a selective advantage to the transforming cells. Hence, our work confirms the natively unstable nature of ATF6 and links this property to potentially associated pro-oncogenic functions.
Introduction
The unfolded protein response (UPR) is an adaptive pathway that either allows the cells to overcome endoplasmic reticulum (ER) stress or promote cell death in the case of overwhelming misfolding burden [1] . Three ER-resident proteins, namely the protein kinase PKR-like ER kinase (PERK), the inositolrequiring enzyme-1 alpha (referred to as IRE1 hereafter), and the activating transcription factor 6 alpha (referred to as ATF6 hereafter) are the major transducers of the UPR in mammals. They display an ER-luminal domain that senses misfolded proteins and are activated by a common mechanism involving the dissociation of the ER chaperone BIP/GRP78. PERK is responsible for translational attenuation through the phosphorylation of the alpha subunit of the eukaryotic translation initiation factor-2 alpha (eIF2a) [2] . IRE1 mediates the unconventional splicing of X-box-binding protein 1 (Xbp1) mRNA together with the tRNA ligase RtcB [3] [4] [5] , promotes degradation of mRNA and microRNA through regulated IRE1-dependent decay (RIDD; [6] ), and controls JNK activation [7] . The third arm of the UPR is controlled by ATF6. This membrane-anchored transcription factor is an ER-resident type II transmembrane protein regulated by intramembrane proteolysis by the Golgi apparatus localized site-1 and site-2 proteases (S1P and S2P) upon ER stress [8] . Recently, it was demonstrated that the ER folding machinery and in particular protein disulfide isomerases were involved in the activation and/or deactivation process of the three ER stress sensors [9, 10] . Moreover, ATF6 was identified as a natively unstable protein [11] , possibly due to the presence of intrinsically disordered regions in its luminal domain, and degraded through proteasomal-dependent mechanisms [12] . ATF6 is classified as an ER-associated degradation (ERAD)-Lm (m = membrane) substrate and the only one in its class to require for its degradation both mannose trimming and the ERAD component SEL1L [13] . Despite this evidence, the precise molecular mechanisms controlling ATF6 activation in the ER remain to be further characterized.
To further investigate the relationships between the molecular machines regulating ER protein quality control (ERQC) and ATF6 activation processes in this compartment, we developed a functional ATF6 ER export screen using small-interfering RNA (siRNA) targeting a panel of well-established ERQC components [14] . Our data highlight the essential contribution of ER glycoprotein quality control mechanisms in the control of ATF6 activation upon ER stress and point toward EDEM1 as a key component of this pathway. To further link this observation to pathophysiology, we took advantage of the recent identification of a somatic mutation in EDEM1 (N198I) that is associated with the development of hepatocellular carcinoma (HCC) [15, 16] . We show that expression of the EDEM1 N198I affects ATF6 activation pattern compared to EDEM1 wild-type under basal conditions thus preconditioning cells to better cope with ER stress. In the context of cancer development, we propose that this mechanism could therefore provide a selective advantage to the mutant cells over their wild-type counterparts.
Results

ATF6 export from the ER upon ER stress
ATF6 is a 90-kDa ER-resident protein and is cleaved to a 50-kDa protein by S1P and S2P proteases in the Golgi apparatus upon ER stress to activate UPR signaling [8] . To confirm whether this phenomenon could be reproduced in our experimental system, we treated HeLa cells with three well-known ER stressinducing chemicals, namely dithiothreitol (DTT, a reducing agent), thapsigargin (Tg, an inhibitor of ER Ca 2+ -ATPase), or tunicamycin (Tun, a N-glycosylation inhibitor). Cell lysates were extracted and analyzed by immunoblotting using anti-ATF6 antibody. Full-length ATF6 (ATF6-p90, black arrowhead) was detected under non-ER stress conditions and active form of this protein (p50-ATF6, white arrowhead) appeared from 30 min after treatment of DTT (Fig. 1A) . ATF6 cleavage was also found in the cells treated with Tg and Tun. Consistent with the previous reports [8, 10, 12, 17, 18] , the non-glycosylated form of p90-ATF6 was detected in Tun-treated cells (Fig. 1A, asterisk) . Furthermore, we found that DTT was the strongest inducer of ATF6 activation. ATF6 is a short-lived protein with 2 h of half-life [8] , and is degraded by the ubiquitin-proteasome system [12] . To test if proteasome inhibition could attenuate the degradation of ATF6 in our experimental condition, HeLa cells were treated with MG132. This analysis showed that MG132 treatment caused the stabilization of p90-ATF6 but not its activation (Fig. 1B) . In the same settings, following treatment with MG132 for 4 h, cells were further treated with DTT, Tg, or Tun. After exposure to ER stress, whole cell extracts were prepared and applied to SDS/PAGE and immunoblotting. This revealed that pretreatment with MG132 enhanced the activation of ATF6 upon ER stress (along with its expression) compared to ER stress alone (Fig. 1C) . Immunofluorescence analysis was also carried out using HeLa cells transiently expressing FLAG-tagged ATF6 protein and DTT as an ER stressor in order to confirm the results in Fig. 1C . Confocal microscopy analysis revealed that fluorescence signals of ATF6 proteins were observed in the perinuclear region of the cells treated with MG132 or vehicle (DMSO) alone and were translocated to the nucleus upon DTT treatment (Fig. 1D) . When HeLa cells were pretreated with MG132 prior to addition of DTT, higher level of ATF6 fluorescence accumulated in the nucleus compared to cells subjected to DTT alone (Fig. 1D) , thereby confirming the immunoblot results. These data indicate a close 
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Tun for the indicated periods of time. Cell lysates were analyzed by immunoblotting using anti-ATF6 antibody. Full-length and cleaved form of ATF6 are indicated as black and white arrowheads, respectively. (D) HeLa cells were transfected with FLAG-ATF6. Twenty-four hours after transfection, cells were either treated with DMSO or 10 mM MG132 for 4 h prior to treatment of 1 mM DTT for 2 h. Cells were then immunostained with anti-FLAG for ATF6 and stained with Hoechst 33342 for nuclei. Cells were analyzed by confocal microscope. Bars, 10 lm.
relationship between ERAD and ATF6 activation process and confirm the natively unstable nature of ATF6.
Identification of EDEM1 as a regulator of ATF6 activation upon ER stress
To further document the molecular mechanisms linking ERQC/ERAD and ATF6 activation, we designed a cell-based siRNA assay against ERQC/ERAD components. Forty-eight hours post-siRNA transfection, the cells were further transfected with the FLAG-ATF6. Twenty-four hours later, the cells were treated with DTT for 2 h to induce ER stress. These cells were then immunostained using anti-FLAG and anti-CNX (ER marker) or anti-Giantin (Golgi complex marker) antibodies as described previously [10] . Cells expressing FLAG-ATF6 protein (number of cells counted ranged from 669 and 22034; Fig. 2A ) were analyzed for the presence of FLAG-ATF6 in the ER, Golgi complex, and nucleus. The percentage of cells displaying both Golgi and nuclear localization of FLAG-ATF6 in each siRNA-transfected cell population was determined and compared to the control siRNA-transfected cells ( Fig. 2A ; primary screen). Among the various ERQC components, only EDEM1 and SEC61alpha were validated in a second screen to indeed affect ATF6 export upon their silencing. As such EDEM1 knockdown led to increased ATF6 export, while SEC61alpha to decreased export of ATF6 to the Golgi complex upon DTT treatment [ Fig. 2B ; siRNA-1 for primary screen, siRNA-2 (green) for validation screen]. To confirm the effect of both EDEM1 siRNAs on their cognate target, we transfected each siRNA into HeLa cells and examined endogenous EDEM1 expression using immunoblot (Fig. 2C) . Transfection of each siRNA (siRNA-1 and siRNA-2) led to significant decrease in EDEM1 expression compared to control siRNA. Both siRNAs neither impacted CNX nor ERK1 expression used as loading standards (Fig. 2C) . ER stress-induced ATF6 activation was also monitored using immunoblotting in HeLa cells. This revealed that silencing of EDEM1 using the siRNAs tested in the screen enhanced ATF6 cleavage upon DTT treatment ( Fig. 2D ; white arrowheads), thus confirming the immunofluorescence data. EDEM1 silencing also led to the stabilization of the full-length ATF6 as soon as 30 min after DTT treatment, an effect also observed upon treatments with Tg and Tun (Fig. 2D ). These data show that EDEM1 contributes to ATF6 stabilization, and thus activation upon ER stress.
EDEM1 silencing enhances ATF6 transcriptional activity
To further demonstrate the effect of EDEM1 silencing on ATF6 activation and the subsequent impact on the transcriptional activation of ATF6 target genes, we measured the expression levels of ATF6 target genes encoding mRNA in control and EDEM1-silenced cells following DTT treatment (1 mM) using quantitative RT-PCR (qPCR). First, we confirmed that the expression of Edem1 mRNA was attenuated by siRNAmediated silencing in both HeLa cells (Fig. 3A) and normal human dermal fibroblasts (NHDFs) (Fig. 3B ).
Then we analyzed the expression of four ATF6 bona fide target genes (Ero1Lb, Grp94, Orp150, and Herpud1) [19, 20] in Hela cells (Fig. 3C ) and the same genes plus four UPR target genes [spliced form of Xbp1 (Xbp1s), Chop, Atf4, Gadd34] in NHDFs upon DTT induced stress and/or silencing of EDEM1 (Fig. 3D ). This revealed that EDEM1 silencing increased the induction of ATF6 target genes upon ER stress without affecting the induction of other UPR targets, such as Xbp1s, Chop, and Gadd34 (Fig. 3C,D) . Interestingly, dose-response with DTT indicated that EDEM1-silenced NHDFs were selectively more sensitive than their non-transfected counterparts for the induction of Orp150 mRNA (Fig. 3E) . Finally, Ero1Lb mRNA expression in NHDFs following DTT treatment differed from that observed in HeLa. This might be indicative of differential redox control between primary cells (NHDFs) and tumor cells (HeLa). Overall, these data show that the effects of EDEM1 silencing on ATF6 activation are conserved in both established cell lines and primary cells in culture thus reinforcing the importance ERQC/ ERAD in ATF6 biology.
Mechanisms of EDEM1-mediated ATF6 regulation
Our results showed that EDEM1 silencing enhances the accessibility of ATF6 activation upon ER stress. As EDEM1 has been involved in ERQC/ERAD for glycoproteins, our results suggested that glycan-dependent ERQC/ERAD mechanisms might be actively involved in the ATF6 activation process most likely in the export from the ER phase. To this end, DTTmediated activation of ATF6 was tested in the presence or absence of the ER alpha-mannosidase I inhibitor, kifunensine (KIF), or of the glucosidase I/II inhibitor, castanospermine (CST). This revealed that KIF enhanced ATF6 activation upon DTT treatment (Fig. 4A) , whereas CST reduced it (Fig. 4B) , thereby confirming that ATF6 glycosylation could be of importance for its activation. The stability of p90-ATF6 was also investigated in response to DTT and upon KIF or CST and DTT treatment (Fig. 4C ). This confirmed that CST treatment increased the stability of ATF6-p90 upon DTT treatment, whereas KIF treatment reduced it. These results were confirmed by the analysis of the induction of two ATF6 target genes Grp94 and Herpud1. Indeed, KIF treatment promoted DTT-mediated induction of both Grp94 and Herpud1 mRNA, whereas CST treatment reduced it (Fig. 4D ). KIF and CST alone did not impact on the expression of those genes (Fig. 4D ). To test whether EDEM1 could act on the stability of ATF6, we determined the half-life of newly synthesized ATF6 under basal conditions upon silencing of EDEM1 or upon treatment with KIF, separately (Fig. 4E ). Quantification analyses revealed that either upon EDEM1 silencing or upon KIF treatment, the stability of ATF6 was increased ( Fig. 4F ). Collectively, these results suggest a tight control of ATF6 availability for activation upon ER stress that is regulated by glycosylation on ATF6.
EDEM1 N198I affects ATF6 activation upon ER stress
ATF6 has already been reported to play an indirect role in hepatocarcinogenesis [21, 22] ; however, the underlying mechanisms still remain uncharacterized. Interestingly, a somatic EDEM1 mutation, N198I (indicated by a gray circle in Fig. 5A ), was identified in hepatocellular carcinoma (HCC) tumors, and specifically in 1 out of 24 samples after whole-exome sequencing analysis with predicted functional consequences [15] . This mutation was found also in another study in 2 tumors out of 243 sequenced [16] . Based on the effect of EDEM1 on the ATF6 activation, observed here, we then sought to determine how this EDEM1 mutant would affect the activation of ATF6 in order to gain some insight into a potential mechanism of ATF6-mediated hepatocellular carcinoma (HCC) development. To test this, HeLa cells were transiently transfected with the FLAG-tagged ATF6 plasmid alone or co-transfected with the wild-type (wt) HA-tagged EDEM1 plasmid or the mutant HA-tagged EDEM1-N198I plasmid, then treated or not with DTT (1 mM) for 0.5, 1, 2, and 3 h. The resulting lysates were immunoblotted with FLAG and EDEM1 antibodies. While overexpression of wt EDEM1 resulted in a kinetics of ATF6 activation similar to that obtained upon overexpression of ATF6 alone but with a smaller activation amplitude, expression of mutant EDEM1 (N198I) led to an early activation of ATF6, with a peak observed after 1 h of DTT treatment and the reduction of ATF6-p50 at 2-3 h compared to wt EDEM1 or ATF6 alone ( Fig. 5C,D) . Moreover, the comparison of the kinetics of p50-ATF6 appearance upon ER stress in cells expressing EDEM1 wt or N198I revealed that EDEM1 N198I mutant accelerated ATF6 activation upon ER stress (Fig. 5E ). In addition, the normalization of the p50-ATF6 levels with the EDEM1 wt or mutant expression levels did not change the differences in the activation mode of ATF6 (Fig. 5F ). Noteworthy, the N198I mutant exhibited a faster electrophoretic mobility than its corresponding wt form as expected by the nature of the mutation on an N-linked glycosylation site (Fig. 5B,  C ). Sequentially, we tested whether this difference in ATF6 activation was due to a change in the physical interaction, if any, between the two proteins. To this end, HeLa cells were transiently co-transfected with the FLAG-tagged ATF6 plasmid and either the wildtype or the mutant form of the HA-EDEM1 plasmid, then immunoprecipitation for HA tag was performed in the lysates which were immunoblotted using anti-FLAG antibodies. After 2 h of DTT treatment, EDEM1 still interacted with the p90-ATF6, and its mutant form also retained the interaction, showing that the alteration in the ATF6 activation is independent of the glycosylation mutation in the EDEM1 (Fig. 5G) . In summary, N198I EDEM1 interacts with ATF6 in the ER as much as the wild-type form does but leads to an accelerated ATF6 cleavage upon ER stress.
EDEM1 expression regulates the stability of fulllength ATF6 under basal conditions
Since ATF6 is a natively unstable protein and since EDEM1 contributes to ERAD, we then tested how the expression of wild-type or N198I EDEM1 could impact on ATF6 stability under basal conditions. To do so, we monitored the expression levels of p90-ATF6 throughout a differential overexpression of EDEM1 wild-type or EDEM1-N198I and in a timecourse fashion. First, increasing amounts of plasmids coding for EDEM1 wild-type or N198I (0-10 lg) were transfected in HeLa cells and the expression levels of p90-ATF6 was monitored (Fig. 6A) . This revealed the minimal concentration (0.5 lg) of plasmid to transfect to observe an effect of the EDEM1 construct on p90-ATF6 (Fig. 6B ). To further evaluate the impact of S-Met pulse and a chase over 5 h followed immmunoprecipitation with anti-FLAG antibodies. Immunoprecipitates were resolved by SDS-PAGE and the gels exposed to X-ray films. (D) ATF6 target genes, Grp94 and Herpud1 mRNA expression upon DTT treatment or not in the presence or absence of KIF or CST. (E) Half-life of ATF6-p90 in cells silenced for EDEM1 or in cells treated with KIF. The amount of ATF6-p90 was determined using immunoblotting with anti-FLAG antibodies (different exposures were used for revealing the X-ray films in the two separate experiments: top and bottom panel). (F) Quantification of (E). . Normalization was carried out with Gapdh. Data are shown as the average of three independent experiments AESD (**P < 0.01, as compared with control). (C) EDEM1 was silenced by siRNA (25 nM) in HeLa cells; after 48 h cells were treated with 1 mM DTT for 2 h. Total RNA was isolated and analyzed by qPCR using specific primers for ATF6 target genes (Ero1Lb, Grp94, Herpud1, and Orp150). Each mRNA expression was normalized to Gapdh mRNA. Data are shown as the average of three independent experiments AESEM (**P < 0.01, as compared with control upon DTT treatment). (D) EDEM1 was silenced by siRNA (25 nM) in NHDFs; after 48 h cells were treated with 1 mM DTT for 2 h. Total RNA was isolated and analyzed by qPCR using specific primers for ATF6 target genes and UPR target genes (Atf4, Chop, Gadd34, and Xbp1s). Each mRNA expression was normalized to Gapdh mRNA. Data are shown as the average of three independent experiments AESEM (*P < 0.05 and **P < 0.01, as compared with control upon DTT treatment). (E) NHDFs were silenced for EDEM1 using siRNA (25 nM) and 48 h later, cells were treated or not with increasing DTT concentrations. Total RNA was isolated and analyzed by qPCR using specific primers for Chop, Gadd34, and Orp150. Each mRNA expression was normalized to Gapdh mRNA. Data are shown as the average of three independent experiments AESEM (**P < 0.01, as compared with control upon DTT treatment). (Fig. 6C,D) , and this in the absence of genuine ER stress (not shown). Collectively, these results show that the N198I EDEM1 mutant is able to prompt the sustained activation of ATF6 thereby activating ATF6 adaptive signaling even in the absence of ER stress.
The same plasmid concentrations of EDEM1 wt or mutant did not yield any difference in the expression of downstream targets of IRE1 and PERK (Xbp1s, Gadd34, Chop, Atf4 mRNAs; Fig. 7 ).
EDEM1 N198I expression increases cell resistance to ER stress through ATF6 signaling
In order to validate the hypothesis according to which the expression of N198I EDEM1 could impact on tumor cells' resistance to ER stress, we monitored survival, apoptosis, and necrosis induction in HeLa and HuH7 cells, the latter being an in vitro model of HCC. In addition to the mutant, the silencing of EDEM1 was also tested in HeLa cells to investigate its effect under ER stress conditions. Silenced cells showed a lower resistance to 4 h of DTT treatment compared to those transfected with the control siRNA (Fig. 8A) , indicating the importance of EDEM1 in the cell survival upon ER stress conditions. Although EDEM1 silencing was found to stabilize ATF6 and favor its activation upon ER stress (Fig. 2) , its absence might also lead to decreased ERAD and consequently increase misfolded proteins accumulation and subsequent proteotoxicity. In addition, both HeLa and HuH7 cells were transiently transfected with either the wild-type or the mutant EDEM1, then treated with DTT (1 mM) or Tun (5 lgÁmL À1 ) for 8, 24, and 48 h, and their survival was evaluated. HeLa cells transiently bearing the N198I EDEM1 showed a greater resistance to DTT treatment, whereas HuH7 cells with the same condition appeared with a greater survival under Tun treatment ( Fig. 8B-E) . Noteworthy, the overexpression of HA-EDEM1 did not lead to complete rescue of the effect seen with the siEDEM1, but with the mutant N198I, the effect was almost completely restored ( Fig. 8A,B ). Cells were also treated with Tg following the same procedure as for DDT or Tun. In those conditions, the expression of either the wild-type or the N198I EDEM1 forms did not yield any survival advantage (data not shown). This was most likely due to the different ways these chemicals induce ER stress. HeLa and HuH7 transiently expressing either EDEM1 wild-type or N198I EDEM1 were treated with 1 mM DTT and tested for apoptosis/necrosis using FACS analysis and Annexin V/7-AAD staining, respectively. While for both HeLa and Huh7 cells induction of apoptosis was not significantly different between the wild-type and N198I EDEM1 forms (Fig. 9A-C) , necrosis was significantly altered in HuH7 cells expressing the mutant N198I EDEM1 compared to wild-type EDEM1 (Fig. 8F) . The effect of the mutant EDEM1 was not observed in basal/untreated conditions; result consistent with the absence of ER stress observed in those cells (Fig. 9D ) and the absence of any significant difference between overexpression of wild-type EDEM1 or mutant EDEM1 on the secretion of a cargo protein, alpha-1 antitrypsin (A1AT; Fig. 10A ). Overexpression of wild-type and N198I EDEM1 was confirmed by immunoblot with anti-EDEM1 antibodies ( Figs 8G and 10A) . Then, to address whether the observed advantage given by the mutant EDEM1 was mediated by ATF6, HuH7 cells were silenced for ATF6 concomitantly with the transfection of HA-EDEM1 and HA-EDEM1-N198I plasmids. Under these conditions, ATF6 silencing yielded same necrosis levels for both wt and mutant EDEM1 (Fig. 8H ). Efficient silencing of ATF6 was confirmed by qPCR analysis (Fig. 8I ) and was also associated with differential effects on cell survival (Fig. 11) . These results indicate that the EDEM1-dependent ATF6 regulation might contribute to a novel survival pathway involved in cancer development.
Discussion
In this manuscript, we aimed at better characterizing the molecular mechanisms of ATF6 activation and evaluate their contribution to cancer development [23] . First, we confirmed that ATF6 can be degraded by the proteasome in our experimental system and showed that proteasome inhibition under ER stress conditions led to a greater ATF6 activation. We thus raised the hypothesis that this improved activation of ATF6 might result from its stabilization. Subsequently, a siRNA-based screening targeting ER quality control components revealed EDEM1 as a regulator of ATF6 activation. Indeed, EDEM1 silencing led to enhanced ATF6 activation, and consequently greater ATF6 transcriptional activity. EDEM1 is a major player in ERAD of glycoproteins through its weak but consistent a1,2-mannosidase activity [24] . EDEM1 downregulation leads to the stabilization of glycosylated ERAD substrates [25] , and is involved in the degradation of ATF6 in non-transformed cells [11] . Our primary siRNA screen also revealed that silencing, EDEM2 or EDEM3, resulted in lower ATF6 Golgi complex and nuclear localization, a marker of activation. This contrasts with the observed effects of EDEM1 silencing and to the previously reported roles of the other EDEMs in non-transformed cells on ATF6 stability [11] and might suggest cell type-dependent roles of EDEM proteins; however, this observation was not confirmed in a secondary screen. ATF6 is a glycoprotein with three N-linked glycosylation sites at the residues 472, 584, and 643. Based on this, we then evaluated ER stress-mediated activation of ATF6 after kifunensine (KIF) or CST treatment and we observed that upon a1,2-mannosidase blockade (KIF) ATF6 was further activated, whereas upon glucosidase inhibition (CST) its activation was greatly reduced (Fig. 4A,B) . This revealed the role of ATF6 glycosylation in its activation process. Moreover, stabilization of ATF6 was also dependent on a1,2-mannosidases in the ER and of EDEM1, thereby indicating the role of ATF6 glycosylation on the protein's presence/availability in the ER. Regarding the role of EDEM1 in this process, it is now known that due to inefficient signal sequence cleavage, EDEM1 can be observed either as a membrane-integrated or as a soluble protein [26] [27] [28] . This topology has been associated with the protein's specificity to either soluble or membranous substrates: soluble EDEM1 leads to faster degradation of the soluble ERAD substrate (ERAD-Ls) null Hong Kong (H) HuH7 cells were transfected with siATF6 (25 nM) for 48 h and HA-EDEM1 (1 lg) or HA-EDEM1-N198I (1 lg) for 24 h, and then cells were treated as in (F). (I) ATF6 qPCR, after normalization to GAPDH mRNA expression levels. Data shown in (A-F) and in (H) are representative of three or more independent experiments and the values shown are the mean AE SEM of the respective experiments (*P < 0.05, **P < 0.01, ***P < 0.001), while data shown for (I) are representative of three technical replicates and the values shown are the mean AE SD of the respective experiments (***P < 0.001 and ****P < 0.0001). Ctl: Control/untransfected; EV: empty vector. (NKH) A1AT, while transmembrane EDEM1 is more efficient in the turnover of the transmembrane TCRa ERAD substrate (ERAD-Lm) [28] . Based on this, one could propose that the ERAD-Lm substrate ATF6 would be mostly controlled by the low abundance membrane-associated EDEM1. EDEM1 exhibits five potential N-glycosylation sites, at the Asn residues 181, 198, 299, 342, and 624. So far, EDEM1 has been observed with either four or five glucans in its final conformation and the difference lies on the final glycosylation site Asn624 [28] . We recently identified a somatic missense mutation on EDEM1 Asn198 (N198I) in hepatocellular carcinoma (HCC) tumors [15, 16] . Since ATF6 has been associated with HCC development [21, 22] , and since its activation was regulated by EDEM1, we reasoned that cancerassociated mutations in EDEM1 might slightly change the protein properties toward ATF6 and therefore promote its adaptive functions, thereby favoring cancer cell growth. Herein, we show that the EDEM1 N198I mutant leads to an altered ATF6 activation pattern under ER stress compared to the wt EDEM1 in HeLa cells. More importantly, the mutant conferred ER stress resistance to both HeLa and HuH7 cells (Fig. 8B-E) . Furthermore, HuH7 cells expressing the EDEM1 N198I mutant were more resistant to ER stress-induced necrosis than cells expressing wt EDEM1. This effect was reversed by knocking down ATF6 indicating its involvement in the cancer advantageous effects of EDEM1 N198I (Fig. 8) . However, our results do not specify the nature of this EDEM1 somatic mutation. Provided that this mutation is rare, it is likely that it is a passenger mutation that enhances pro-tumorigenic properties through the stabilization of ATF6 and its subsequent enhanced activation.
Co-immunoprecipitation experiments showed that EDEM1 N198I interacts with ATF6 as efficiently as wild-type EDEM1, thus suggesting that additional factors should be involved. A first possibility might be that EDEM1 N198I enzymatic activity could be further reduced thus reducing the entry of ATF6 into ERAD. A second possibility might rely on a reduced association of EDEM1 N198I with SEL1L leading to the subsequent reduced association with ATF6 in a dynamic manner [28] . Interestingly, ATF6, which is the only SEL1L-dependent ERAD-Lm substrate [13] , was further activated upon SEL1L silencing. As a result, the fastest activation of ATF6 caused by EDEM1 N198I could be due to an inefficient/slower delivery to the SEL1L-containing complex, thus attenuating the subsequent ATF6 degradation and increasing its availability for transport to the Golgi complex. Remarkably, EDEM1 N624 was reported to be essential for EDEM1 maturation but without effect on the turnover of NHK A1AT; however, the effect on a membrane ERAD substrate was not tested. Following the same logic, one could postulate the intervention of other ERAD machinery components involved in the observed effect of the mutant EDEM1 or alternatively the impact of altered EDEM1 glycosylation on its availability in the ER. However, this would not be specific to the ATF6 protein but would also include other ERAD-Lm substrates.
Hence, this study reveals the role of EDEM1-mediated regulation of ATF6 activation in transformed/cancer cells. Moreover, an HCC-associated somatic mutation of EDEM1 (N198I) was functionally studied and found to promote ATF6 activation under basal conditions thereby enhancing cell resistance to ER stress most likely through an hormesis-like mechanism. These data might provide an explanatory mechanism for the proposed pro-oncogenic role of ATF6 in primary liver cancers.
Materials and methods
Materials
Mouse monoclonal anti-ATF6 was from BioAcademia. Mouse monoclonal anti-FLAG M2, DTT, MG132 (Z-LeuLeu-H), thapsigargin (Tg), and CHX were obtained from Sigma-Aldrich (St. Louis, MO, USA). Rabbit polyclonal anti-Giantin antibody was from Abcam. Goat polyclonal anti-EDEM1, goat polyclonal anti-Actin, and rabbit polyclonal anti-ERK1 antibodies were from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). Mouse monoclonal anti-HA was obtained from Roche (Basel, Switzerland). Rabbit anti-CNX antibody was kindly provided by Dr. John Bergeron (McGill University, Montreal, QC, Canada). CST, kifunensine (KIF), and tunicamycin (Tun) 
Plasmids
Human ATF6 cDNA was amplified from human total cDNA by PCR and cloned into p3xFLAG-CMV7.1 vector within the HindIII/SalI restriction sites. pCMV-SPORT2-EDEM1-HA was kindly provided by Dr. Ikuo Wada (Fukushima medical University, Fukushima, Japan). pCMV-SPORT2-EDEM1(N198I)-HA was generated by QuickChange Ò II XL site-directed mutagenesis kit (Stratagene, San Diego, CA, USA).
Cell culture and transfection
HeLa and Huh7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS and penicillin-streptomycin (100 UÁmL À1 and 100 lgÁmL À1 , respectively) at 37°C in a 5% CO 2 incubator. HeLa cells stably expressing 3xFLAG-ATF6a (HeLa-ATF6) [10] were maintained in DMEM with 10% FBS containing 200 lgÁmL À1 Hygromycin B (Invitrogen). FLAG-tagged ATF6 (FLAG-ATF6), HA-EDEM1, and HA-EDEM1-N198I proteins were transiently transfected in HeLa and HuH7 cells using Lipofectamine and PLUS reagents or Lipofectamine 2000 (Thermo-Fisher Scientific) according to the manufacturer's protocols.
RNA interference
Small-interfering RNAs (siRNA) were obtained from RNAi Co. (Tokyo, Japan) and Thermo-Fisher Scientific. Each siRNA (25 nM) was transfected into HeLa, HeLa-ATF6, or HuH7 cells by reverse transfection using Lipofectamine RNAiMAX (Invitrogen). The sequences of siRNA used in this study are described in Table S1 .
Immunoblot and immunoprecipitation
Whole cell extracts were prepared using either RIPA buffer (25 mM Tris/HCl pH 7.5, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, and 0.1% SDS) or SDS sample buffer (50 mM Tris/HCl pH 6.8, 2% SDS, 10% glycerol) after washing cells with ice-cold PBS. To prepare the lysates for the detection of ATF6 using a mouse monoclonal anti-ATF6, cells were lysed in SDS sample, mixed vigorously and boiled for 5 min. To prepare the extracts for other proteins, the cells were incubated in RIPA buffer for 30 min on ice and cell lysates were centrifuged at 4°C for 20 min at 10 000 g. The samples were applied to SDS/ PAGE and analyzed by immunoblotting. Dilutions of primary antibodies used for immunoblotting were as follows:
mouse monoclonal anti-ATF6, 1 : 1000; rabbit polyclonal anti-CNX, 1 : 2000; goat polyclonal anti-EDEM1, goat polyclonal anti-Actin, 1 : 1000; rabbit polyclonal anti-ERK, 1 : 1000; mouse monoclonal anti-FLAG M2, 1 : 2000; mouse monoclonal anti-HA, 1 : 1000. For the immunoprecipitation analysis, the cells were lysed in CHAPS buffer (30 mM Tris/HCl pH7.5, 150 mM NaCl, and 1.5% CHAPS) and then incubated 16 h at 4°C with the HA antibody (1 lg Ab/1000 lg protein). After this, dynabeads protein G (Life Technologies) were first washed with CHAPS lysis buffer and/or PBS, then mixed with the protein/Ab mixture, incubated at room temperature for 20 min with gentle rotation and washed with CHAPS and/ or PBS. Finally, the beads were eluted with 19 Laemmli sample buffer, heated at 55°C for 5 min and loaded to SDS/PAGE. For the immunoblotting, anti-FLAG M2 was used as described before.
Indirect immunofluorescence
HeLa cells transiently expressing FLAG-ATF6 were cultured on coverslips in 24-well plate and fixed in methanol at À20°C for 5 min. Then, cells were blocked in immunofluorescence buffer (0.15 M NaCl, 2 mM EGTA, 1 mM MgCl 2 , and 10 mM PIPES-Na pH 7.2) containing 3% bovine serum albumin for 30 min and incubated with primary (anti-FLAG M2, 1 : 500; anti-CNX, 1 : 500 or anti-Giantin, 1 : 1000) and secondary (Alexa-488 labeled anti-mouse IgG or Alexa-568 labeled anti-rabbit IgG, 1 : 250, respectively) antibodies for 1 h at room temperature. Nuclei were stained using Hoechst 33342 (Invitrogen). Coverslips were mounted on microscope slides using Fluoromount-G (Thermo-Fisher Scientific) and observed using a Leica TCS SP5 confocal microscope with 639 oil immersion objective.
Quantitative RT-PCR (qPCR)
Total RNA was extracted from 48 h after siRNA-transfected cells using TRIZOL reagent (Invitrogen) according to the manufacturer's instruction. cDNA was synthesized from the total RNA using SuperScript First-Strand Synthesis System (Invitrogen) or Reverse Transcription System (Promega, Fitchburg, WI, USA) with Oligo(dT) primer (Thermo-Fisher Scientific). cDNA was analyzed with B-R SYBR Green SuperMix (Quanta Biosciences, Berverly, MA, USA) in StepOnePlus TM system (Applied Biosystems). The primer sequences used for this experiment are shown in Table S2 .
S-methionine pulse-chase experiments
Expression of EDEM1 in HeLa-ATF6 was silenced by 25 nM of siRNA for 72 h. Cells were then incubated in methionine-and cysteine-free DMEM with 10% DMEM for 2 h. KIF (5 lgÁmL
À1
) was added to HeLa-ATF6 cells
Supporting information
Additional supporting information may be found online in the Supporting Information section at the end of the article. Table S1 . List of siRNAs used for screening and knockdown experiments. Table S2 . List of primers used for qPCR.
